Physician profile
Bryan Lusk
NPI 1700043643
$9,582.02
in general payments reported to CMS, 2019-2025
25 companies · $603 in 2025
The $603 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,338 · 2020: $680 · 2021: $816 · 2022: $607 · 2023: $1,260 · 2024: $4,278 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,800 · Education: $2,000 · Travel and Lodging: $1,145 · Entertainment: $170 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,800.44 |
| Education | $2,000.00 |
| Travel and Lodging | $1,145.33 |
| Entertainment | $169.87 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $2,257.44 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Bausch & Lomb Americas INC. | $1,744.45 | 2023-2025 | Stellaris Elite, Envista Aspire Iol, Teneo |
| Alcon Vision LLC | $1,439.55 | 2019-2025 | Clareon, Lensx, Rocklatan |
| Abbvie INC. | $597.33 | 2022-2025 | |
| Allergan, INC. | $514.15 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $413.40 | 2019-2021 | |
| Glaukos Corporation | $356.46 | 2019-2024 | Idose, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Oyster Point Pharma, INC. | $283.23 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $254.80 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $236.34 | 2020-2023 | Cequa |
| Mallinckrodt Hospital Products INC. | $234.33 | 2023-2025 | Acthar |
| Biotissue Holdings INC. | $181.32 | 2021-2023 | |
| Optos, INC. | $169.87 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Kala Pharmaceuticals, INC. | $163.37 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $148.55 | 2019-2025 | Tecnis Simplicity |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $144.14 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $143.28 | 2019-2021 | |
| Sight Sciences, INC. | $64.96 | 2021-2022 | |
| Harrow Eye, LLC | $58.58 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $48.03 | 2024-2025 | Xdemvy |
| Thea Pharma INC. | $43.64 | 2022-2023 | Iyuzeh |
| Shire North American Group INC | $34.06 | 2019 | |
| Horizon Therapeutics Plc | $18.41 | 2023 | Tepezza |
| Omeros Corporation | $16.88 | 2021 | |
| Cardinal Health 200 LLC | $15.45 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Lusk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.